An inexpensive and rapid test for tuberculosis (TB) which could be used in developing countries has won first place in the Best Innovation to Improve Global Healthcare category of the Medical Fut
A diagnostics test developed by the University of Liverpool for monitoring anti-HIV drugs in the blood is to be made available across Europe. The test has been acquired by Delphic Europe - a dia
A new optical instrument that could vastly reduce the amount of time the pharmaceutical industry spends in R&D, by speeding up the measurement of drug inhaler performance, is being launched by Loughbo
A novel "Flu Chip" developed at the University of Colorado at Boulder that can determine the genetic signatures of specific influenza strains from patient samples within hours may help world health o
Robots, both large and micro, can potentially go wherever it's too hot, cold, dangerous, small or remote for people to perform any number of important tasks, from repairing leaking water mains to stitching blood vessels together. Now
LGC, Europe's leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis, has announced an exclusive agreement with
Three young scientists in the University of York's Department of Chemistry have developed a gel that could spare cancer patients some of the unpleasant and dangerous side-effects of radiothe
The U.S. Food and Drug Administration (FDA) is throwing it's weight behind a policy that would mean implantable heart defibrillators would be returned to their manufacturers to be studied for possible def
A single cell with the potential to repair damaged heart muscle tissue . . . regenerate injured bone . . . create new cartilage or skin . . . even reverse nerve damage. Human stem cells offer tremendous hope for the development of revolutionary medical
Penn State researchers recently were awarded a $5 million contract from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a pediatric heart assist device. "This contract will
Date: Monday, 11-Dec-2006
An advisory panel for the Food and Drug Administration (FDA) in the U.S. has recommended that the drug-coated stents used in patients with cardiovascular disease should carry a warning.The panel says the popular stents, which are mesh tubes used to keep arteries open after an angioplasty, are implanted in as many as one million Americans each year.
The panel of experts are concerned over two brands in particular Taxus, made by Boston Scientific and Cypher, made by Cordis, a division of Johnson & Johnson which hit the markets in 2003 and 2004.
The stents provided a non-surgical alternative to bypass surgery for many patients with artery disease but it is now thought they may increase the risk of heart attacks and sudden deaths by as much as 0.5 percent per year, beginning a year after implantation.
When new data was released earlier in the year questioning the safety of the devices the FDA quickly assembled an expert panel to decide on a course of action.
The panel has suggested that the benefits of the drug-coated stents outweigh the risks for average patients but the problem has arisen because the original approval for the stents was granted after the devices had been tested in patients with single, smaller artery blockages; however many doctors soon started to use them in patients with blockages in multiple vessels and in those with larger blockages or additional diseases such as diabetes.
According to the FDA such 'off-label' use of the drug-coated stents means that 60 percent or more of all implants are being done in patients for whom they were not intended with the result that more complicated patients are put at an increased risk of dangerous blood clots, heart attack and sudden death.
The advisory panel has also said that the use of the blood-thinning drug Plavix should be extended from six months to one year in patients who receive drug-coated stents off-label.
The recommendations which were the consensus of the panel members, will be made public and communicated to both patients and doctors but the experts say there is no need for patients with the drug-coated stents to have them removed as clots and heart attacks associated with the stents are relatively rare.
Experts and researchers believe the new warnings will lead to a more conservative use of the drug coated stents and many doctors may now revert to traditional bypass surgery for patients with multiple blockages or diabetes.